ISO 42001 for Pharma: AI Governance Guide for GxP Teams

What Is ISO 42001 and Why Are Pharma Teams Asking About It?

ISO/IEC 42001:2023 is the first international management system standard for artificial intelligence. It was published in December 2023 and follows the same harmonized structure as ISO 9001:2015, with clauses 4 through 10 covering context, leadership, planning, support, operation, performance evaluation, and improvement. If your site already runs a quality system, the skeleton will feel familiar.

Pharma teams are asking about it for a practical reason. AI is showing up in places that were once purely deterministic: deviation triage, literature surveillance for pharmacovigilance, visual inspection, predictive maintenance, batch release analytics, and document drafting. Each of those touches a regulated process, and most quality units I talk with do not yet have a single place where those AI uses are inventoried, risk-assessed, and controlled.

That gap is what ISO 42001 addresses. It does not tell you how to validate a model for a GMP use. It tells you how to run an organization that develops, provides, or uses AI systems responsibly, with defined roles, risk assessment, impact assessment, and continual improvement.

In my view, the right question for a pharma company is not "should we get certified?" It is "do we have a governed way of deciding which AI is allowed near a regulated decision, and can we show that to an inspector?" ISO 42001 is one credible way to build that.

Does ISO 42001 Replace GxP Validation or FDA Expectations?

No. ISO 42001 is a voluntary management system standard. Certification to it does not demonstrate compliance with FDA or EU requirements, and I am not aware of any regulator that treats it as a substitute for existing obligations. The regulations you already live under stay in force:

• 21 CFR Part 11 for electronic records and signatures
• 21 CFR 211.68 for automatic, mechanical, and electronic equipment in drug manufacturing, including computer systems
• 21 CFR Part 820, which since the Quality Management System Regulation took effect on February 2, 2026 incorporates ISO 13485:2016 by reference for device manufacturers
• EU GMP Annex 11 for computerised systems
• ICH Q9(R1) for quality risk management and ICH Q10 for the pharmaceutical quality system

The useful way to think about it is layering. GxP validation answers whether this specific system is fit for its intended use. ISO 42001 answers whether the organization has a repeatable way to govern AI across all of its uses, including ones that never hit a validation protocol, like a data scientist's notebook or a vendor's embedded feature.

How the Pieces Fit Together

What Is the Regulatory Landscape for AI in Pharma Right Now?

Three documents deserve attention, and you should read the originals rather than rely on summaries, including mine.

FDA's January 2025 draft guidance is titled "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products." It proposes a risk-based credibility assessment framework built around a defined question of interest and a context of use. It is draft guidance, so it represents FDA's current thinking rather than a binding requirement, and it is scoped to AI used to produce information supporting regulatory decisions about safety, effectiveness, or quality. It is not aimed at AI used purely for internal efficiency, such as drafting or resource allocation.

The EU AI Act, Regulation (EU) 2024/1689, sets risk tiers and phased obligations. Most pharma uses of AI in manufacturing and quality will not be classified as high-risk on their own, but AI that is a safety component of a regulated medical device, or that is itself a device subject to third-party conformity assessment, can be pulled into the high-risk category through Article 6. Confirm the current application dates against the Official Journal text and any amendments, because timelines have been under active discussion.

The draft EU GMP Annex 22 on Artificial Intelligence, released for public consultation in July 2025 alongside proposed revisions to Annex 11, takes a narrow position. As drafted, it addresses static, deterministic models used in critical GMP applications and treats dynamic, continuously learning models and generative AI as unsuitable for critical applications. Check the status of the final text before you build procedures around it, since drafts change.

Put those together and a pattern emerges: regulators want a defined intended use, evidence the model performs for that use, human oversight where it matters, and change control. ISO 42001 gives you the management system to produce that consistently.

Which ISO 42001 Clauses Matter Most for Pharma?

The standard has 10 clauses and an Annex A with 38 controls grouped under 9 control objectives. You do not need all of it to be equally heavy in a pharma setting. These are the parts I would put the most effort into.

Clause 4: Context of the Organization

Clause 4.1 asks you to determine external and internal issues relevant to your AI purpose, and 4.2 asks for interested parties and their requirements. For pharma, the interested parties list is longer than most AI teams expect: FDA, EMA and national competent authorities, notified bodies, contract manufacturers, sponsors, patients, and your own quality unit. Clause 4.3 requires you to define scope, and scope decisions matter a great deal. A scope limited to "AI used in GxP-relevant processes" is far more defensible and manageable than "all AI everywhere."

Clauses 6.1.2 to 6.1.4: AI Risk Assessment, Treatment, and Impact Assessment

This is the center of the standard. Clause 6.1.2 requires a defined AI risk assessment process, 6.1.3 covers risk treatment and the Statement of Applicability against Annex A, and 6.1.4 requires an AI system impact assessment. The operational counterparts are 8.2, 8.3, and 8.4.

Pharma teams already know risk management from ICH Q9(R1), so the work here is mostly mapping. Your existing severity, probability, and detectability logic can carry over, but you need to add AI-specific sources of risk: training data representativeness, model drift, lack of explainability, third-party model dependency, and misuse. The impact assessment goes beyond product quality to affected individuals and groups, which for pharma includes patient safety and data integrity.

If risk-based thinking is still maturing in your quality system, the practical guide on risk-based thinking in ISO 9001 is a good foundation, because ISO 42001 assumes you can do it well.

Annex A: The Controls That Map Naturally to GxP Habits

Annex A is organized around policies, internal organization, resources, assessing impacts, the AI system life cycle, data, information for interested parties, use of AI systems, and third-party relationships. Several of these already look like things a pharma quality unit does:

• AI system life cycle (Annex A.6): requirements, design, verification and validation, deployment, operation, and monitoring. This lines up with a computerised system life cycle under GAMP 5.
• Data for AI systems (Annex A.7): data quality, provenance, and preparation. This is ALCOA+ thinking applied to training and test data.
• Third-party and customer relationships (Annex A.10): supplier responsibilities and allocation of responsibilities. This sits next to your supplier qualification program.

The Statement of Applicability lets you justify exclusions. If you do not develop AI systems and only use vendor tools, some life cycle controls will apply differently, and you can say so with reasoning.

Clause 8.1: Operational Planning and Control

This is where intended use, change control, and outsourced processes come together. If a vendor updates a model underneath you, that is a change to a process you are responsible for. The same discipline discussed in outsourced process control under ISO 9001 applies directly, and I would argue it is the single most underestimated risk in pharma AI adoption today.

How Do You Implement ISO 42001 in a Regulated Pharma Environment?

Here is the sequence I recommend. It is deliberately boring, because boring is what inspectors like.

Step 1: Build the AI Inventory

You cannot govern what you cannot list. Ask every function what AI they use, including embedded features in LIMS, QMS, ERP, and document tools, plus anything staff are using on their own. Record the purpose, the process it touches, the data it sees, the vendor, and whether it influences a GxP decision. Expect the first list to be about half the real list. Run it a second time after you announce a policy.

Step 2: Classify by Decision Impact

Sort each use into tiers based on what happens if the output is wrong. A model that helps an author draft a meeting summary sits in a different place than a model that dispositions an inspection image or prioritizes deviations. This classification becomes the backbone of your risk assessment under clause 6.1.2 and aligns naturally with the context-of-use thinking in FDA's draft guidance.

Step 3: Write the Policy and Assign Roles

Clause 5.2 requires an AI policy and clause 5.3 requires assigned roles and authorities. In pharma, decide early whether AI governance sits inside the quality unit, in IT, or in a cross-functional committee. My preference is a committee chaired by quality with IT, data science, regulatory, and the business owner at the table. Whichever you choose, write down who can approve a new AI use and who can stop one.

Step 4: Integrate With Your Existing Quality System

Avoid building a parallel bureaucracy. Add AI-specific requirements to the procedures you already have: change control, deviation management, supplier qualification, training, document control, and CAPA. Clause 7.5 on documented information can usually be satisfied by extending your current document hierarchy.

Step 5: Define Human Oversight and Performance Monitoring

For each higher-tier use, document what the human reviews, what authority they have to override, and what performance metrics trigger investigation. Clause 9.1 requires monitoring, measurement, analysis, and evaluation, so pick metrics that are actually measurable, such as false negative rate on a known challenge set, and set acceptance criteria before go-live.

Step 6: Audit and Review

Clause 9.2 requires internal audits and 9.3 requires management review. Your internal audit program can take this on once auditors are trained on AI-specific risks. The structure described in the internal audits resource transfers well, though you will want someone in the room who understands data and models.

Step 7: Decide on Certification

Certification is optional. It makes sense when customers, partners, or contract organizations are asking for independent assurance, or when you want an external check on the governance you have built. It makes less sense if the aim is to impress a regulator, since the regulator will be looking at your actual controls and your validation evidence. Use an accredited certification body, and ask how their auditors are qualified for AI.

What Are the Common Mistakes Pharma Companies Make?

Treating the standard as a validation protocol. Teams read Annex A, see "verification and validation," and assume a model is now validated. It is not. You still need a documented intended use, representative test data, acceptance criteria, and a conclusion that fits your computerised system validation approach.

Scoping too wide or too narrow. Wide scope produces a system nobody can maintain. Narrow scope leaves the highest-risk uses outside the boundary. Start with GxP-relevant uses and expand with intent.

Ignoring vendor models. Most pharma AI exposure today comes from tools you buy rather than models you build. Your supplier agreements need to cover model change notification, training data use, performance data sharing, and audit rights. Review the approach in purchasing controls and supplier evaluation when you update your qualification criteria.

Skipping the impact assessment. The impact assessment under clause 6.1.4 is easy to treat as a form. In my experience it is where the best conversations happen, because it forces the team to say who could be harmed and how.

Letting generative AI sit outside the system. If staff are using public generative tools with confidential or regulated data, that is a data integrity and confidentiality problem long before it is an AI governance problem. A clear acceptable use position, with a sanctioned alternative, usually works better than a ban.

ISO 42001 vs ISO 9001 vs ISO 13485: Which Do You Need?

These standards answer different questions, and a pharma or device organization may reasonably use more than one.

Because 42001 uses the same high-level structure as ISO 9001, organizations with an existing certified system can integrate them rather than run separate manuals. If you are earlier in the journey, the ISO 9001 implementation overview explains how that shared structure works in practice.

What Does a Reasonable Timeline Look Like?

It depends on how much of your AI footprint you already know. As a rough planning view, the inventory, scoping, and policy work can often be done within a quarter if leadership engages. Risk and impact assessments for higher-tier uses take longer, particularly where you depend on vendors for documentation. Internal audit and management review need to happen before a certification audit, so build in time for findings to be closed.

I would rather see a company take a year and have controls that people use than rush to a certificate and discover that nobody follows the process. The most telling sign of readiness is not the document set. It is whether a quality manager can explain, without notes, why a given AI use was approved and what would make you withdraw it.

Where Should You Start This Week?

Pick one AI use that touches a GxP decision and walk it through the questions in clause 6.1.2 and 6.1.4. Who owns it? What is the intended use? What happens if it is wrong? What evidence would convince an inspector? If you can answer those cleanly, you are closer than you think. If you cannot, you have found the first real work, and that is a better place to begin than any gap analysis template.

Jared Clark, JD, MBA, PMP, CMQ-OE, CQA, CPGP, RAC, is Principal Consultant at Certify Consulting (https://certify.consulting).

Last updated: 2026-10-11

Frequently Asked Questions

Is ISO 42001 required for pharmaceutical companies?

No. ISO/IEC 42001:2023 is a voluntary management system standard. FDA and EU regulators do not require it, and certification does not demonstrate compliance with 21 CFR Part 11, EU GMP Annex 11, or other existing requirements.

Does ISO 42001 certification replace computerised system validation?

No. Validation shows that a specific system is fit for its intended use. ISO 42001 governs how the organization approves, assesses, monitors, and improves AI across all its uses. The two work together.

Which ISO 42001 clauses are most relevant to pharma?

Clauses 6.1.2 (AI risk assessment), 6.1.3 (risk treatment and Statement of Applicability), 6.1.4 (AI system impact assessment), and 8.1 (operational planning and control) carry the most weight, along with Annex A controls on the AI system life cycle, data, and third-party relationships.

How does ISO 42001 relate to the EU AI Act?

ISO 42001 is a voluntary management standard, while Regulation (EU) 2024/1689 is binding law. The standard can support the governance processes that help meet AI Act obligations, but certification alone does not prove legal compliance.

Can ISO 42001 integrate with an existing ISO 9001 or ISO 13485 system?

Yes. ISO 42001 uses the same harmonized clause structure as ISO 9001:2015, so document control, internal audit, management review, and corrective action processes can usually be extended rather than duplicated.